



Monsenso to participate in AI-enabled personalised mental health therapy project

13.12.2022 09:25:14 CET | Monsenso | Company Announcement

Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.

Company announcement no. 15-2022

Monsenso (publ.) (Nasdaq First North Growth Market Denmark: Ticker MONSO) is obligated to publish the information in compliance with the EU Market Abuse Regulation.

Copenhagen, 2022.12.13

Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.

With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso's platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.

- With this project, we will further develop our platform's ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients' own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients' actual state, so that patients are offered the right treatment at the right time in a scalable way, says Thomas Lethenborg, CEO of Monsenso.

Full disclosure of the project details including consortium members, funding program and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.

Financial expectations

The project does not impact Monsenso's financial expectations for 2022, but it is expected to contribute to the growth in 2023 and beyond.

Further information:

Monsenso:

CEO

Thomas Lethenborg

Tel. +45 21 29 88 27

E-mail: lethenborg@monsensio.com

Chairman of the board

Peter Mørch Eriksen

Tel. +45 51 99 66 00

E-mail: petermorcheriksen@outlook.com

Certified Adviser:

Norden CEF A/S

John Norden

Tel. +45 20 72 02 00

E-mail: jn@nordencef.dk

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com

Attachments

- [Download announcement as PDF.pdf](#)
- [Patient with smartphone.jpg](#)
- [Clinician with clinical web portal.jpg](#)